AbbVie (NYSE:ABBV) Price Target Raised to $249.00 at Guggenheim

Key Points

• Guggenheim raised its price target on AbbVie to $249 and kept a "buy" rating, implying about a 16.6% upside from the prior close.
• Analyst views are mixed — MarketBeat's consensus is a Moderate Buy with an average price target of $253, reflecting 2 Strong Buy, 14 Buy and 9 Hold ratings.
• AbbVie beat quarterly EPS ($2.71) and revenue expectations, but recent cuts to near-term guidance and notable insider stock sales have weighed on the stock.

AbbVie (NYSE:ABBV - Get Free Report) had its price objective increased by analysts at Guggenheim from $242.00 to $249.00 in a research report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's price target would suggest a potential upside of 16.57% from the company's previous close.

Several other equities research analysts have also recently issued reports on the stock. Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research report on Tuesday, January 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price objective for the company. Morgan Stanley lifted their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Finally, UBS Group cut their price target on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $253.00.

AbbVie Stock Up 1.0%

ABBV opened at $213.61 on Friday. AbbVie has a twelve month low of $164.96 and a twelve month high of $244.81. The firm has a 50 day moving average price of $220.65 and a 200-day moving average price of $224.11. The stock has a market capitalization of $377.70 billion, a price-to-earnings ratio of 90.51, a PEG ratio of 0.76 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie will post 12.31 earnings per share for the current year.

Insider Transactions at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Norges Bank acquired a new stake in AbbVie during the 4th quarter valued at approximately $5,865,055,000. Wellington Management Group LLP lifted its position in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Capital World Investors boosted its holdings in AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company's stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. raised its stake in shares of AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock valued at $1,244,112,000 after buying an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after buying an additional 4,190,487 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie sued HHS and the federal government seeking a narrower definition of who qualifies as a 340B patient — a move that, if upheld, could reduce discounted sales and protect revenue/margins. AbbVie files lawsuit to address 'outdated' drug discount eligibility program
• Positive Sentiment: Dividend resilience remains a tailwind: AbbVie's payout history and yield keep it appealing to income investors, supporting downside defense in the stock. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Neutral Sentiment: Analyst takes are mixed: some outlets frame ABBV as fairly valued or a buy with caveats, highlighting pipeline potential (immunology drugs Skyrizi/Rinvoq) but also valuation and competition concerns. AbbVie: Fairly Valued And Positioned For Growth
• Neutral Sentiment: Marketing/competitive signals: J&J recently retook the top spot in TV drug ad spending from AbbVie — a tactical datapoint about promotional intensity but not an immediate earnings driver. J&J's Tremfya retakes TV drug ad spending crown from AbbVie
• Negative Sentiment: AbbVie cut its Q1 2026 EPS guidance to $2.56–$2.60 (consensus ~3.01) and FY 2026 to $13.96–$14.16 (consensus ~14.56), a direct driver of today's downward pressure as investors re-rate near-term earnings visibility.
• Negative Sentiment: Cantor Fitzgerald lowered its price target on ABBV to $240 from $250 and warned Q1 likely won't “dramatically reinvigorate” the story — a notable sell-side tilt that can amplify short-term selling. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.